Jefferies Group’s C4 Therapeutics CCCC Stock Holding History

Jefferies Group’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-11,530	Closed	-$382K	–	1663
2020 Q4	$382K	Buy	+11,530	New	+$334K	﹤0.01%	1220

Other funds holding CCCC

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jefferies Group's CCCC Position: Q1 2021 in Review

Jefferies Group sold out of C4 Therapeutics (CCCC) in Q1 2021, closing a stake of 11,530 shares — an estimated $382K sold.

Jefferies Group first reported a position in CCCC in Q4 2020 and held it in 1 quarter. The position peaked at $382K in Q4 2020. 83 funds tracked by Wall St. Rank hold CCCC as of Q1 2021.

Jefferies Group reported no remaining C4 Therapeutics position as of Q1 2021 after selling out during the quarter.
Jefferies Group sold 11,530 C4 Therapeutics shares in Q1 2021, an estimated $382K.
Jefferies Group first reported a position in C4 Therapeutics in Q4 2020 and held it in 1 quarter.
Jefferies Group's C4 Therapeutics position peaked at $382K in Q4 2020.
83 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2021.

Based on Jefferies Group's 13F filing for Q1 2021, filed 14 May 2021.